Literature DB >> 7992834

Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas.

C R Boschman1, S Stryker, J K Reddy, M S Rao.   

Abstract

To evaluate the incidence and stage at which p53 alterations occur in human pancreatic carcinogenesis, we examined primary and metastatic carcinomas, carcinoma in situ, and hyperplastic lesions with and without atypia for p53 protein overexpression by immunohistochemical procedure. Overexpression of p53 was observed in 40% (10/25) of primary tumors, 29% (2/7) of metastatic tumors, 36% (5/14) of carcinoma in situ, and 35% (6/17) of hyperplastic lesions. These results suggest that p53 protein overexpression is not only a common genetic alteration but also occurs very early in the development of these tumors. It is suggested that p53 overexpression can be used as a marker to identify precursor lesions that have increased potential to develop into malignant tumors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7992834      PMCID: PMC1887505     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  28 in total

Review 1.  A genetic model for colorectal tumorigenesis.

Authors:  E R Fearon; B Vogelstein
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

2.  Overexpression of p53 protein in adenocarcinoma of the pancreas.

Authors:  J A DiGiuseppe; R H Hruban; S N Goodman; M Polak; F M van den Berg; D C Allison; J L Cameron; G J Offerhaus
Journal:  Am J Clin Pathol       Date:  1994-06       Impact factor: 2.493

3.  Participation of p53 protein in the cellular response to DNA damage.

Authors:  M B Kastan; O Onyekwere; D Sidransky; B Vogelstein; R W Craig
Journal:  Cancer Res       Date:  1991-12-01       Impact factor: 12.701

4.  Relation of pancreatic duct hyperplasia to carcinoma.

Authors:  S Kozuka; R Sassa; T Taki; K Masamoto; S Nagasawa; S Saga; K Hasegawa; M Takeuchi
Journal:  Cancer       Date:  1979-04       Impact factor: 6.860

5.  An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms.

Authors:  I O Baas; J W Mulder; G J Offerhaus; B Vogelstein; S R Hamilton
Journal:  J Pathol       Date:  1994-01       Impact factor: 7.996

6.  Morphological lesions associated with human primary invasive nonendocrine pancreas cancer.

Authors:  A L Cubilla; P J Fitzgerald
Journal:  Cancer Res       Date:  1976-07       Impact factor: 12.701

Review 7.  Biology of pancreatic cancer.

Authors:  G J Poston; J Gillespie; P J Guillou
Journal:  Gut       Date:  1991-07       Impact factor: 23.059

8.  p53 gene mutations in Barrett's epithelium and esophageal cancer.

Authors:  A G Casson; T Mukhopadhyay; K R Cleary; J Y Ro; B Levin; J A Roth
Journal:  Cancer Res       Date:  1991-08-15       Impact factor: 12.701

9.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.

Authors:  C Almoguera; D Shibata; K Forrester; J Martin; N Arnheim; M Perucho
Journal:  Cell       Date:  1988-05-20       Impact factor: 41.582

10.  High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas.

Authors:  K Grünewald; J Lyons; A Fröhlich; H Feichtinger; R A Weger; G Schwab; J W Janssen; C R Bartram
Journal:  Int J Cancer       Date:  1989-06-15       Impact factor: 7.396

View more
  28 in total

Review 1.  Molecular biology of pancreatic ductal adenocarcinoma progression: aberrant activation of developmental pathways.

Authors:  Andrew D Rhim; Ben Z Stanger
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

2.  Hedgehog/Ras interactions regulate early stages of pancreatic cancer.

Authors:  Marina Pasca di Magliano; Shigeki Sekine; Alexandre Ermilov; Jenny Ferris; Andrzej A Dlugosz; Matthias Hebrok
Journal:  Genes Dev       Date:  2006-11-15       Impact factor: 11.361

3.  Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer.

Authors:  Sally E Dowen; Tatjana Crnogorac-Jurcevic; Rathi Gangeswaran; Mikkel Hansen; Jyrki J Eloranta; Vipul Bhakta; Teresa A Brentnall; Jutta Lüttges; Gunther Klöppel; Nick R Lemoine
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

4.  Clinical significance of serum p53 antigen in patients with pancreatic carcinomas.

Authors:  H Suwa; G Ohshio; N Okada; Z Wang; M Fukumoto; T Imamura; M Imamura
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

5.  Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer.

Authors:  Yi Zhong; Anne Macgregor-Das; Tyler Saunders; Martin C Whittle; Alvin Makohon-Moore; Zachary A Kohutek; Justin Poling; Brian T Herbst; Breanna M Javier; Leslie Cope; Steven D Leach; Sunil R Hingorani; Christine A Iacobuzio-Donahue
Journal:  Clin Cancer Res       Date:  2016-09-16       Impact factor: 12.531

Review 6.  Advances in biomarker research for pancreatic cancer.

Authors:  Kruttika Bhat; Fengfei Wang; Qingyong Ma; Qinyu Li; Sanku Mallik; Tze-Chen Hsieh; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

7.  An immunohistochemical study of the expression of bcl-2 and p53 oncoproteins in pancreatic intraepithelial neoplasia and pancreatic cancer.

Authors:  R Tomaszewska; D Karcz; J Stachura
Journal:  Int J Pancreatol       Date:  1999-12

8.  Clinical implication of anti-p53 antibodies and p53-protein in pancreatic disease.

Authors:  Gakuji Ohshio; Hirofumi Suwa; Masayuki Imamura
Journal:  Int J Gastrointest Cancer       Date:  2002

9.  Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse.

Authors:  Nabeel Bardeesy; Andrew J Aguirre; Gerald C Chu; Kuang-Hung Cheng; Lyle V Lopez; Aram F Hezel; Bin Feng; Cameron Brennan; Ralph Weissleder; Umar Mahmood; Douglas Hanahan; Mark S Redston; Lynda Chin; Ronald A Depinho
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

10.  p53 protein expression and CA19.9 values in differential cytological diagnosis of pancreatic cancer complicated with chronic pancreatitis and chronic pancreatitis.

Authors:  De-Qing Mu; Guo-Feng Wang; Shu-You Peng
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.